Immune response to COVID‐19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T‐cell response

Myeloma patients frequently respond poorly to bacterial and viral vaccination. A few studies have reported poor humoral immune responses in myeloma patients to COVID‐19 vaccination. Using a prospective study of myeloma patients in the UK Rudy study cohort, we assessed humoral and interferon gamma re...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramasamy, Karthik, Sadler, Ross, Jeans, Sally, Weeden, Paul, Varghese, Sherin, Turner, Alison, Larham, Jemma, Gray, Nathanael, Carty, Oluremi, Barrett, Joe, Bowcock, Stella, Oppermann, Udo, Cook, Gordon, Kyriakou, Chara, Drayson, Mark, Basu, Supratik, Moore, Sally, McDonald, Sarah, Gooding, Sarah, Javaid, Muhammad K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Covid‐19
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306522/
https://www.ncbi.nlm.nih.gov/pubmed/35064676
http://dx.doi.org/10.1111/bjh.18066

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306522/
https://www.ncbi.nlm.nih.gov/pubmed/35064676
http://dx.doi.org/10.1111/bjh.18066

Ejemplares similares